Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fujisawa to market newly-cleared Adenoscan

This article was originally published in Clinica

Executive Summary

Medco Research (US) has received US FDA marketing approval for its Adenoscan coronary vasodilator for use in nuclear perfusion imaging. The agent, for coronary artery disease assessment in patients unable to undergo exercise stress testing, will be manufactured and marketed in North America by Fujisawa USA. The two companies have settled their respective lawsuits following a two-year legal battle in which Medco alleged that Fujisawa delayed Adenoscan's launch (see Clinica No 592, p 21). Details of the settlement were not disclosed.

You may also be interested in...



Singapore And Malaysia Test Joint Evaluation Of Generics

A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.

Australia Looking Into In-Vitro Self-Test Deregulation

In-vitro self-tests for influenza and sexually transmitted diseases as well as direct-to-consumer genetic tests are on the agenda for deregulation in Australia. 

ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery

ConMed Corp. is company of two halves  ̶  general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.

Topics

UsernamePublicRestriction

Register

MT091675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel